DNA oligonucleotides block viral entry of SARS-CoV-2 Omicron variants
PLOS Pathogens · 30.07.2026 · 22 (7) · e1014461
DOI: 10.1371/journal.ppat.1014461 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 30.07.2026. Verfasst von Jorge A Acuña und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States o…. Hauptthemen laut MEDLINE: SARS-CoV-2, Virus Internalization, Oligodeoxyribonucleotides, COVID-19. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, Burroughs Wellcome Fund.
Abstract (Originalsprache)
Successful viruses including SARS-CoV-2 antagonize and evade immune detection to establish infection. As population immunity to the ancestral strain has risen, new variants—particularly Omicron—have evolved to avoid detection by both circulating antibodies and the innate immune system. Screening innate immune agonists, we previously identified STING agonists as potent inhibitors of the ancestral variant of SARS-CoV-2. When we explored the sensitivity of Omicron BA.1 to diverse innate stimuli, we found that Omicron is also sensitive to interferons and STING agonists; however, Omicron variants are uniquely restricted by small DNA oligonucleotide ligands known to activate TLR9. Mechanistic studies showed that short, but not long, DNA oligonucleotides of diverse sequences, including those that do not engage TLR9, block Omicron infection at an entry step downstream of TMPRSS2-mediated activation. Using genetic and pharmacological assays we confirmed that activity was independent of TLR9. Furthermore, these oligodeoxynucleotides (ODNs) are active in vivo , reducing SARS-CoV-2 Omicron titers. Together, these findings identify a previously unrecognized antiviral activity of short DNA oligonucleotides and establish them as selective inhibitors of SARS-CoV-2 Omicron entry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
- Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
- Center for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
- Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
ORCID-Profile: Sara Cherry
Förderung
- NIAID NIH HHS
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- Burroughs Wellcome Fund
- Deans Innovation Fund
- the Linda and Laddie Montague Foundation
Zitieren
APA
Acuña, J. A., Gabriel, B., Ayyanathan, K., Miller, J., Li, Y., Whig, K., Zhu, Y., McGrath, M., Hewins, P., Jurado, K. A., Frieman, M. B., Schultz, D. C., & Cherry, S. (2026). DNA oligonucleotides block viral entry of SARS-CoV-2 Omicron variants. PLOS Pathogens, 22(7), e1014461. https://doi.org/10.1371/journal.ppat.1014461
Vancouver
Acuña JA, Gabriel B, Ayyanathan K, Miller J, Li Y, Whig K, et al. DNA oligonucleotides block viral entry of SARS-CoV-2 Omicron variants. PLOS Pathogens. 2026;22(7):e1014461. doi:10.1371/journal.ppat.1014461
BibTeX
@article{Acua2026,
author = {Acuña, Jorge A and Gabriel, Benjamin and Ayyanathan, Kasirajan and Miller, Jesse and Li, Yue and Whig, Kanupriya and Zhu, Yongqing and McGrath, Marisa and Hewins, Peter and Jurado, Kellie Ann and Frieman, Matthew B and Schultz, David C and Cherry, Sara},
title = {DNA oligonucleotides block viral entry of SARS-CoV-2 Omicron variants},
journal = {PLOS Pathogens},
year = {2026},
volume = {22},
number = {7},
pages = {e1014461},
doi = {10.1371/journal.ppat.1014461}
}
EUVIMED